We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ondine Biomedical Inc. | OBI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -1.00 | -12.12% | 7.25 | 08:33:54 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.25 | 7.25 | 8.25 | 7.25 | 8.25 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 31/5/2024 20:00 by purple11 OBI BUY HOLD ADD112p xXTiPSXHEETSXx |
Posted at 31/5/2024 15:07 by purple11 no losses in obi ppp or ondosmall loss in zed on 2nd trade first trade covered it qed nice trade not too shabby |
Posted at 16/5/2024 12:15 by purple11 how much PROFIT is OBI making at the moment?And how much is OBI diluting its stock at present? LOL |
Posted at 10/5/2024 07:12 by z1co 10/05/2024:ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or the "Company") ECDC report shows HAIs are increasing antibiotic use A third of microorganisms causing HAIs (healthcare-associat Ondine Biomedical (LON: OBI): A recent report from the European Centre for Disease Prevention and Control (ECDC) helps underscore the need for Ondine's light-activated antimicrobial technology, a much-needed innovation in the face of growing antibiotic resistance. The report reveals an alarming increase in antibiotic use and rising resistance and finds that 4.3 million patients in EU/EEA hospitals are affected by healthcare-associate The report, "Point prevalence survey of healthcare-associate ECDC Director Dr. Andrea Ammon said: "Healthcare-associat With the threat of antibiotic-resistant HAIs increasing year-on-year, there is a growing need for effective antimicrobials which do not generate resistance. Antimicrobial resistance (AMR) is responsible for 1.27 million deaths a year and is one of humanity's most urgent global public health threats.[1] Ondine's Steriwave light-activated antimicrobial technology is highly effective against all types of pathogens-viruses, bacteria and fungi-including those that cause HAIs, even those resistant to antibiotics. Steriwave is a broad-spectrum light-activated antimicrobial that uses a patented photosensitizer and associated red light to destroy pathogens in the nose. The nose is a major reservoir of bacteria, fungi, and viruses, which can spread from there to cause serious infections. Unlike traditional antibiotics, Steriwave is immediately effective with a single five-minute treatment and does not trigger AMR. In 2023, Ondine presented research at the 2023 International Consortium on Prevention & Infection Control (ICPIC) in Geneva, demonstrating that Steriwave was highly effective (>99.99% kills in 20 seconds) against both moderately drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria.[2] Ondine's Steriwave technology is already used in the UK in the NHS and extensively in hospitals across Canada to prevent HAIs. In 2024, hospitals in Spain became the first in the EU to adopt this groundbreaking technology. The prestigious Hospital Universitario La Paz (HULP), a large tertiary hospital in Madrid with 1,308 beds, is one of three Spanish hospitals using Steriwave. According to the latest ECDC HAI surveillance report, the prevalence rate of HAIs in Spain is 8.2% compared to the median of 6.8%. Spain also had higher rates of antibiotic usage, with over 45% of patients with an HAI receiving antibiotics. More than 150,000 patients have been treated with Steriwave to date, and no serious side effects have been reported. |
Posted at 24/4/2024 07:22 by bamboo2 Corporate and Trading UpdateSignificant revenue growth and commercial momentum Ondine Biomedical (LON: OBI), a leading provider of light-activated antimicrobial technology to treat and prevent hospital infections, provides an update on its recent developments, strategic priorities and 2024 corporate plans. Commercial In 2023, revenues nearly doubled to $1.2 million ($0.6 million in 2022), driven by significant growth in the number of hospitals deploying Steriwave®. Ondine ended the year with 16 hospital deployments, up from six at the prior year end. This momentum has continued with eight additional hospital deployments in Q1 2024, bringing the total to 24 hospitals, 50% up from the previous year-end and four times the number at the beginning of 2023. During the last quarter, several hospitals announced expansions to include other surgical indications. The Company is also benefitting from significantly reduced sales cycle times, lower new client acquisition costs and improved margins resulting from lower cost of goods and higher product pricing. Retention of hospital accounts added to date is at 100%. Of the eight new hospital placements in the first quarter of 2024, five of these were located internationally: · In the UK, strategic inroads were made into the NHS in England with the accelerated adoption by two hospitals in the Mid Yorkshire NHS Teaching Trust (the "Trust") for orthopedic surgeries as a result of a strong early pilot data in one of them, and high levels of enthusiasm for the new technology by both healthcare professionals and patients. The Trust created a 12-month budget for the use of Steriwave for patients undergoing hip and knee surgery. Ondine is now partnering with the Trust and Health Innovation Yorkshire and Humber to conduct a health economic analysis to further support Steriwave adoption across the NHS. In the private sector, HCA Healthcare UK has approved Steriwave for use in its UK-based private hospitals, at the discretion of the clinician. HCA UK, a leading private healthcare provider in the UK with 30 facilities, is a subsidiary of HCA Healthcare (USA). · In Spain, the first three hospitals are now implementing Steriwave, including the prestigious Hospital Universitario La Paz (HULP). HULP is a large tertiary hospital in Madrid with 1,308 beds. The Hospital Universitario La Paz is recognized as a centre of reference and health excellence and is considered one of the top three public hospitals with the best reputation in Spain. · In Australia, Ondine has achieved its first hospital deployment in Australia at Mater Hospital, North Sydney, a 233-bed private hospital in New South Wales. The hospital is part of the St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services. This follows the recent Australian Spine Society Conference held from 5-7 April 2024, at which Dr. John Street, Co-Medical Director of the Complex Spine Program at Vancouver General Hospital, presented his research study findings on Steriwave as keynote speaker. Distribution Partnership(s) to accelerate growth: As a result of Ondine's positive clinical data, growing sales momentum and recent commercial success, the Company has been approached by several multinational companies in the hospital supply, wound care, and infection control industries. The Company is currently in a process of progressing discussions on distribution collaborations with potential partners. While these discussions have been constructive, there is no certainty that a distribution agreement will materialize from any of these discussions. Management believes that distribution partnerships have the potential to generate earlier income for Ondine in the form of time-based territorial license payments and to accelerate sales and income generation for the Company through faster market penetration and greater geographical reach. The Company's 2023 investments in manufacturing capacity upgrades combined with a significant COGS reduction program support larger-scale rollout and increased gross margins required by any potential partners. The latest generation light diffuser is reducing the cost of goods for our Steriwave testing kits by 46 per cent. Expansion into Intensive Care Units (ICU): Ondine is accelerating its plans to enter the ICU market to take advantage of interest by hospitals to replace the commonly used antibiotic mupirocin. Mupirocin, the topically applied antibiotic used in the nose over 5 days, requires lengthy administration times and generates antibiotic resistance. Having established a solid safety and efficacy profile in over 150,000 patients in pre-surgical and industrial settings, the Company estimates that the ICU application represents an opportunity to expand the total addressable market for Steriwave significantly. As ICUs have the highest hospital rates of infection and mortality, they represent an opportunity to accelerate new hospital adoption at a point of major unmet need both in terms of improving patient outcomes and reducing cost of care and length of stay. Further announcements will be made in due course. US Phase 3 Clinical Trial Plans Following a Type C meeting with the US Food & Drug Administration ("FDA") last September, the design and budget for the clinical trial program has been finalized in close collaboration with HCA Healthcare ("HCA"), Ondine's US clinical trial partner. The trial will run at 14 HCA hospital sites with a circa 5,000-patient group-randomized crossover study, comparing Ondine's nasal photodisinfection added to standard-of-care infection prevention practices versus standard-of-care alone. The Company is targeting to commence the trial in the third quarter of this year. Data from the trial will inform the Company's planned FDA submission and approval would facilitate adoption of Steriwave in the US. Funding Position and Support The Company has received indications of support from its founder CEO and substantial shareholder, Carolyn Cross, and from other existing shareholders, to provide near-term funding to extend the Company's runway. Discussions are currently underway with HCA's investment arm, Health Insight Capital, for its funding support of the key Phase 3 clinical trial. The Company is confident in its ability to secure longer-term financing to execute on the growth opportunities described above. Further announcements will be made in due course. |
Posted at 22/4/2024 08:23 by bamboo2 Steriwave in first Australian hospitalMater Hospital, North Sydney has become the first Australian hospital to use Ondine Biomedical's award-winning light-activated antimicrobial technology Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Mater Hospital, North Sydney, a private hospital in New South Wales, has become the first Australian hospital to start using its light-activated antimicrobial Steriwave® technology to prevent the spread of hospital-acquired infections (HAIs). Mater Hospital, located in North Sydney and founded in 1906, is part of St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services. Medical Oncologist, Professor Frances Boyle AM, Director of the Patricia Ritchie Centre for Cancer Care and Research at Mater Hospital and Professor of Medical Oncology at the University of Sydney, said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose - a major source of infection transmission - is a benefit to our patients." Orthopaedic Spine Surgeon Dr John Street, Director of the Integrated Ambulatory Spine Program at Vancouver Coastal Health and upcoming President of the Canadian Spine Society, was a keynote speaker at the recent 2024 Spine Society of Australia 35th Annual Scientific Meeting that was held in Sydney on April 5-7th, 2024. Dr Street presented the results of his team's 14-year study evaluating Steriwave's effect on SSIs following spine surgery at Vancouver General Hospital ("VGH"), concluding that Steriwave nasal photodisinfection should be part of routine use and recommended it as standard of care for all elective and emergent spine surgeries. The VGH research involved 13,493 patients and demonstrated a 66.5% reduction (7.98% vs 2.67%, p<0.001) in surgical site infections (SSIs) following spine surgery when Ondine's Steriwave nasal photodisinfection (nPDT) was implemented in the universal pre-surgical infection prevention protocol. The researchers also found average net annual cost saving of $2.49 million, a saving of over $2,400 per spine surgery patient, post rollout. |
Posted at 04/4/2024 07:48 by bamboo2 Entry into ICU market expands revenue potentialFollowing interest from Canadian Hospitals, Ondine prepares to enter the Intensive Care Unit (ICU) market · Treatment of patients in ICUs would significantly expand Ondine's potential market opportunity. · Hundreds of thousands of patients are admitted to the ICU every year in Canada alone, with an average stay of over four days.[1] · One in every eight patients in Canadian ICUs develops an infection not related to their presenting medical illness.[2] · Daily nasal decolonisation with Ondine's new light-activated antimicrobial treatment, Steriwave®, which does not generate antimicrobial resistance (AMR), could help prevent these life-threatening infections. · ICUs in Canada, the UK and the EU are being targeted under existing regulatory approvals. Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that interest from hospitals in Canada has accelerated its opportunity to address the Intensive Care Unit (ICU) market. Already used in hospitals across Canada to reduce HAIs (healthcare-associat The opportunity for hospital cost savings by using Steriwave is very substantial. One study found that patients who develop an HAI in ICU typically spend 30 days in the hospital compared to around three days for non-HAI patients.[3] The average daily cost for an ICU bed in Canada is $3,592, three times higher than a standard ward bed. Longer ICU stays also lead to ongoing higher overall health costs.[4] Similar to its outcomes for pre-operative nasal decolonisation of surgical patients, Ondine anticipates substantial cost savings for the hospital as well as a significant reduction in mortality rates. A large study involving nearly 75,000 patients, amounting to more than 280,000 patient days in 74 adult ICUs, was carried out in 2012 by HCA Healthcare, the US's largest hospital group, and demonstrated the effectiveness of daily nasal decolonisation for patients in ICUs. The study found that universal nasal decolonisation using the antibiotic mupirocin reduced all-cause bloodstream infections by 44%.[5] However, hospitals are becoming increasingly reluctant to routinely treat patients with mupirocin, the most commonly used standard of care, because of rising resistance rates of up to 80%, leaving few approved alternatives to this major antimicrobial resistance (AMR) problem.[6] Carolyn Cross, CEO of Ondine Biomedical Inc., commented, "We have long known that the ICU is an epicenter of hospital infection due to the vulnerable population of critically ill patients and the high use of invasive procedures including intubation, catheters and ports. We believe that Steriwave can offer a far more effective solution to ICU infections than nasal antibiotics, and we are looking forward to capitalising on this large market segment. Ondine will be able to reach ICUs using its existing sales and marketing infrastructure, making this an obvious area for us to expand into." Ondine has regulatory approvals in Canada, Mexico, the UK, and Europe that cover using Steriwave in the ICU. Steriwave works as a broad-spectrum antimicrobial that uses a photosensitizer solution and associated red activating light to destroy pathogens that colonise the nose and can spread to cause harmful infections. Unlike traditional antibiotics, Steriwave is immediately effective with a single five-minute treatment and does not trigger antimicrobial resistance (AMR). Steriwave has now been used in over 150,000 patient treatments, including at major hospitals across Canada and more recently in early-adopting NHS hospitals. |
Posted at 26/1/2024 07:28 by z1co ONDINE BIOMEDICAL INC.("Ondine Biomedical", "Ondine", or the "Company") Ondine unveils new research at SPIE Photonics West Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present new research at the SPIE Photonics West conference in San Francisco, California. The presentation will provide details of an exploratory study showing that photodisinfection significantly reduces pathogens in the nose - a reservoir for bacteria - yet does not produce long-term adverse effects on the nasal microbiome.1 Organised by SPIE, the international society for optics and photonics, SPIE Photonics West is the largest annual event for optic and photonic technologies and one of the largest scientific conferences in the world. These results demonstrate that Steriwave is an effective, potent, short-acting, and non-selective method of nasal decolonization, while permitting rapid recovery of the native microbiome at one week after treatment. The study involved analyzing nasal swabs from 35 healthy volunteers after being treated with Ondine's Steriwave® Nasal Photodisinfection System. The oral presentation will be delivered by Ondine's Director of Research and Development, Dr Caetano Sabino, at 9am on Tuesday, 30 January 2024, as part of the "Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases" session. The "Microbiome Analysis of Photodynamic Nasal Decolonization" abstract can be accessed here. _________ 1 The nasal microbiome consists of a complex community of microorganisms - fungi, parasites, viruses, and bacteria - that can act in a symbiotic relationship in the nasal cavity. |
Posted at 09/11/2023 22:19 by z1co Grandpa beeksy this is for to read and try to understand if you can:Steriwave shown to reduce resistant bacteria by >99.9% -- New research presented by Ondine shows that Steriwave photodisinfection reduces antibiotic-resistant bacteria by more than 99.9% without generating resistance. -- The research suggests that photodisinfection is a viable alternative to antibiotics. Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) is today presenting new research showing that Steriwave (R) photodisinfection reduced antibiotic-resistant bacteria by more than 99.9%. The in vitro study, which is being presented today at the IP2023 Annual conference taking place in Liverpool 17-19 October 2023, indicates that photodisinfection is likely to play an important role in strategies for combatting antimicrobial resistance (AMR). The controlled study evaluated the efficacy of Ondine's Steriwave (R) photodisinfection against Gram-negative and Gram-positive multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria with novel antibiotic resistance factors. All of the bacterial strains used in the study exhibited resistance against some of the most commonly prescribed antibiotic classes, including penicillin, tetracyclines, quinolones and carbapenems. The results of the study showed that treatment with photodisinfection resulted in >99.9% reduction of viable bacteria compared to the control, regardless of the antibiotic susceptibility of the bacteria. The authors concluded that photodisinfection is likely an important adjunct to AMR strategies in the future and that further clinical studies are warranted. Antimicrobial resistance (AMR) remains a major public health concern, causing 33,000 deaths in Europe annually ([1]) which is projected to rise to over 10 million globally by 2050. ([2]) There are widespread multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections across the world which are mainly caused by Gram-negative bacteria including Enterobacteriaceae and P. aeruginosa AMR bacteria ([3]) (, [4]) and Gram-positive bacteria such as Staphylococcus spp. ([5]) Steriwave has been found to be highly effective against all these pathogens. Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation. Carolyn Cross, CEO of Ondine, commented: "We continue to demonstrate, both clinically in hospitals across Canada and in the lab, that photodisinfection can provide a real alternative to topical antimicrobials which are no longer effective against an increasing number of pathogens. The evidence continues to show that photodisinfection destroys all types of pathogens including viruses, bacteria and fungi even those in biofilm, and we believe this technology can save millions of lives. The results of this study are particularly welcome as we prepare for our US Phase 3 trial in partnership with HCA Healthcare who are providing invaluable guidance and support." |
Posted at 18/10/2023 07:50 by bamboo2 Ondine Biomedical Inc. Steriwave shown to reduce resistant bacteria18/10/2023 7:00am RNS Non-Regulatory TIDMOBI Ondine Biomedical Inc. 18 October 2023 18 October 2023 ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine" or the "Company") Steriwave shown to reduce resistant bacteria by >99.9% -- New research presented by Ondine shows that Steriwave photodisinfection reduces antibiotic-resistant bacteria by more than 99.9% without generating resistance. -- The research suggests that photodisinfection is a viable alternative to antibiotics. Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) is today presenting new research showing that Steriwave (R) photodisinfection reduced antibiotic-resistant bacteria by more than 99.9%. The in vitro study, which is being presented today at the IP2023 Annual conference taking place in Liverpool 17-19 October 2023, indicates that photodisinfection is likely to play an important role in strategies for combatting antimicrobial resistance (AMR). The controlled study evaluated the efficacy of Ondine's Steriwave (R) photodisinfection against Gram-negative and Gram-positive multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria with novel antibiotic resistance factors. All of the bacterial strains used in the study exhibited resistance against some of the most commonly prescribed antibiotic classes, including penicillin, tetracyclines, quinolones and carbapenems. The results of the study showed that treatment with photodisinfection resulted in >99.9% reduction of viable bacteria compared to the control, regardless of the antibiotic susceptibility of the bacteria. The authors concluded that photodisinfection is likely an important adjunct to AMR strategies in the future and that further clinical studies are warranted. Antimicrobial resistance (AMR) remains a major public health concern, causing 33,000 deaths in Europe annually ([1]) which is projected to rise to over 10 million globally by 2050. ([2]) There are widespread multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections across the world which are mainly caused by Gram-negative bacteria including Enterobacteriaceae and P. aeruginosa AMR bacteria ([3]) (, [4]) and Gram-positive bacteria such as Staphylococcus spp. ([5]) Steriwave has been found to be highly effective against all these pathogens. Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation. Carolyn Cross, CEO of Ondine, commented: "We continue to demonstrate, both clinically in hospitals across Canada and in the lab, that photodisinfection can provide a real alternative to topical antimicrobials which are no longer effective against an increasing number of pathogens. The evidence continues to show that photodisinfection destroys all types of pathogens including viruses, bacteria and fungi even those in biofilm, and we believe this technology can save millions of lives. The results of this study are particularly welcome as we prepare for our US Phase 3 trial in partnership with HCA Healthcare who are providing invaluable guidance and support." The poster presentation, "Antimicrobial Photodynamic Therapy Against Extensively Drug-Resistant (XDR) Gram Negative Isolates With Novel Antibiotic Resistance Factors", is being presented at IP2023 between 1:10pm and 2:40pm (BST) on 18 October 2023. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
